Allen Capital Group’s AnaptysBio ANAB Stock Holding History

Allen Capital Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273K	Sell	4,039 -85	-2%	-$5.15K	0.02%	256
2026 Q1	$229K	Buy	+4,124	New	+$222K	0.02%	255

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Allen Capital Group's ANAB Position: Q2 2026 in Review

Allen Capital Group reduced its AnaptysBio (ANAB) stake by 2.1% in Q2 2026, selling an estimated $5.15K and leaving 4,039 shares worth $273K. The position accounts for 0.02% of the portfolio, ranked #256.

Allen Capital Group first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Allen Capital Group held 4,039 shares of AnaptysBio worth $273K as of Q2 2026.
Allen Capital Group sold 85 AnaptysBio shares in Q2 2026, an estimated $5.15K.
AnaptysBio made up 0.02% of Allen Capital Group's portfolio in Q2 2026, its #256 holding.
Allen Capital Group first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Allen Capital Group's 13F filing for Q2 2026, filed 27 Jul 2026.